T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone.
T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone.
复制标题
骨髓增生异常综合征患者的 T 细胞通常源自恶性克隆。
DOI：
10.1111/j.1365-2141.2011.08872.x
复制
发表时间：
2012
影响因子：
6.5
通讯作者：
Karsan,Aly
中科院分区：
文献类型：
--
作者：
Vercauteren,SuzanneM;Starczynowski,DanielT;Sung,Sandy;McNeil,Kelly;Salski,Chris;Jensen,Clara-Lynn;Bruyere,Helene;Lam,WanL;Karsan,Aly
T cell clonality is a common finding in patients with myelodysplastic syndrome (MDS), but is currently thought to be a reactive phenomenon (van Lom et al, 1995; Epling-Burnette et al, 2007). Recent evidence points to a stem or multipotent progenitor cell as the MDS-initiating cell in some patients, suggesting that the lymphoid lineage may also be involved in the disease. Clonal circulating myeloid and lymphoid precursor dendritic cells have been detected in patients with MDS (Ma et al, 2004) and a high percentage of monosomy 7 in pluripotent stem cells, B cell progenitors and T/Natural Killer (NK) progenitor cells was reported in three of four MDS patients analysed (Miura et al, 2000). In a series of MDS cases that progressed to T cell acute lymphoid leukaemia (T-ALL), the MDS karyotypic aberration was also detected in the T-ALL cells (Disperati et al, 2006).Many genome-wide studies in MDS have used CD3+ cells from the same patient to represent a patient normal control in order to distinguish between constitutional and acquired variants (Starczynowski et al, 2008). The present study investigated whether T cells are derived from the malignant MDS clone using DNA microarrays in 40 MDS patients.
